Humanized anti-CXCR5 antibodies, derivatives thereof and their use

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9228019
APP PUB NO 20130236476A1
SERIAL NO

13794224

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • SANOFI

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Allen, Elizabeth Stewartsville, US 17 68
Baurin, Nicholas St Germain les Arpajon, FR 8 2
Cameron, Beatrice Paris, FR 49 280
Lee, Renata Edison, US 9 12
Mikol, Vincent Charenton-le-Pont, FR 48 606
Oligino, Thomas Forks Township, US 11 13
Ruetsch, Norman Moorestown, US 9 12

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 5, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00